Published in FDA Law Weekly, November 24th, 2005
An analysis of data on patients who have completed 9 months of follow-up to date revealed a numerical trend favoring the Taxus stent over Johnson & Johnson's Cypher sirolimus-eluting stent system in reducing major adverse cardiovascular events (MACE) and target vessel revascularization (TVR). The interim results were presented at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.